Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Build A Bear Workshop Inc (BBW) vs Eli Lilly And Co (LLY) Price & Performance

Build A Bear Workshop IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Build A Bear Workshop Inc vs Eli Lilly And Co — how do they compare? Build A Bear Workshop Inc trades at $32.95 (market cap $412.61M), while Eli Lilly And Co trades at $1,153.9 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 2496.3× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays the higher dividend (2.8%). Which is the better fit depends on your goals.

BBWLLY
Market Cap
$412.61M$1.03T
Sector
Consumer CyclicalHealth
52-Week High
$75.85$1.24K
52-Week Low
$29.84$625.65
Enterprise Value
$512.05M$1.07T
Dividend Yield
2.8%0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Build A Bear Workshop Inc

Build-A-Bear Workshop (BBW) trades at $33.62, down 2.32% with a bullish technical signal and strong valuation metrics including a P/E of 7.71 and P/S of 0.81. The company maintains solid profitability with 10.48% net margins and 35.87% ROE, while recent earnings have consistently beaten expectations. CEO transition to Chris Hurt in June 2026 and new product launches support growth initiatives.

BBW presents compelling value with analyst consensus target of $62.50 (86% upside) and 73% buy ratings. Strong fundamentals and debt-free balance sheet support long-term growth, though near-term headwinds include consumer spending pressure and international expansion execution risks.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.

The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Build A Bear Workshop Inc

Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.

Read more on BBW

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY